New Treatments Target Tumor Cell Clusters to Stop Metastasis

Researchers are investigating novel treatments designed to disrupt clusters of circulating tumor cells to impede the process of cancer metastasis. According to reporting from Science on April 9, 2026, the most effective method to curb the spread of cancer may be to prevent these clusters, described as roaming gangs of tumor cells, from forming in the first place.

Metastasis occurs when tumor cells migrate from the original primary site through the bloodstream to establish new tumors in other parts of the body. This process is identified as the primary reason for high mortality rates among cancer patients.

The Role of Circulating Tumor Cells

Circulating tumor cells (CTCs) are cells that detach from primary tumors and enter the bloodstream. Once in circulation, these cells can travel to distant sites to establish metastatic colonies.

Research published in J Nanobiotechnology on June 17, 2025, indicates that CTCs often do not travel alone. They frequently form heterotypic clusters by interacting with white blood cells, with a particular emphasis on neutrophils. These interactions assist the tumor cells in establishing distant metastatic sites.

The formation of these clusters is a critical stage in cancer dissemination. By targeting the interactions between CTCs and neutrophils, scientists are exploring nanoengineered strategies to inhibit the spread of the disease.

Targeting Cluster Stability and Signaling

Different therapeutic approaches are being tested to break up these cell clusters or prevent their stability. One such approach involves the use of Hirudin.

According to research published in Nature, Hirudin suppresses hematogenous metastasis. It achieves this by targeting the desmosome junction transition within circulating tumor cell clusters, specifically utilizing the HIF-1α–DSG2 signaling pathway.

By disrupting these junctions, the stability of the tumor cell clusters is compromised, which may reduce their ability to successfully colonize distant organs.

Epigenetic Mechanisms of Metastasis

Beyond the physical clustering of cells, epigenetic modifications play a significant role in how CTCs behave and spread. A 2024 review in Nature highlights the importance of DNA methylation in regulating gene expression and chromosome stability.

Two specific types of changes in DNA methylation patterns are pivotal to carcinogenesis:

• Global hypomethylation
• Locus-specific hypermethylation

These modifications impact several critical stages of CTC dissemination, including the epithelial-mesenchymal transition (EMT), immune surveillance, and the eventual colonization of new tissues. Understanding these epigenetic changes provides a pathway for identifying new biomarkers for early detection and developing targeted therapies.

Current Treatment Landscape and Future Directions

While research into disrupting CTC clusters is ongoing, other small-molecule inhibitors are already used to treat metastatic cancers. For example, Regorafenib, an oral multikinase inhibitor, is an approved treatment for metastatic colorectal cancer.

However, the prognosis for patients with metastatic cancer remains persistently poor despite these therapeutic efforts. This underscores the necessity of developing treatments that can stop the metastatic process at the bloodstream stage.

The current scientific focus is shifting toward the early stages of bloodborne spread. By combining nanoengineered strategies to block neutrophil interactions, signaling inhibitors like Hirudin to break junctions, and a deeper understanding of DNA methylation, researchers aim to bridge the gap between basic laboratory research and clinical application to improve patient outcomes.